Provided by Tiger Trade Technology Pte. Ltd.

AQR Capital Holdings

2,685.43
+29.831.12%
Number of Gainers:57
Number of Losers:39
Number of Flat:2
PE:- -
High:2,697.11
Open:2,655.45
Low:2,655.45
Close:2,655.60
Volume:1.18B
Turnover:239.15B
Market Cap:49.12T
Float Cap:45.71T

Loading ...

BlackRock American Income Trust NAV at 277.43p Including Income, 276.94p Capital-Only

Reuters
·
Sep 24

Grafton Resources Secures Exclusive Option to Buy Newmont’s Chilean Poseidon and Jabali Projects for Us$2.54 Million

Reuters
·
Sep 24

Health Canada Approves AbbVie’s Epkinly Combo for Relapsed or Refractory Follicular Lymphoma in Adults

Reuters
·
Sep 24

IBM Acquires UK Cybersecurity Consultancy Logiq Consulting

Reuters
·
Sep 24

P&G to Webcast First-Quarter Earnings Discussion

Reuters
·
Sep 24

Ibm Acquires Logiq Consulting to Expand Secure Digital Transformation and Cybersecurity Capabilities in the UK

THOMSON REUTERS
·
Sep 24

Ibm - Financial Details of Ibm-Logiq Consulting Deal not Disclosed

THOMSON REUTERS
·
Sep 24

Italy's Giglio.com H1 Revenue Falls, Net Loss Widens

Reuters
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

IBM Unveils Two Capabilities to Expand Digital Banking Infrastructure

MT Newswires Live
·
Sep 24

Oracle, Wild Bioscience Collaborate on AI-Driven Agriculture Research Using Oracle Cloud, IoT

Reuters
·
Sep 24

Amazon Adds Prime Delivery Option, Discounts Fulfillment Fees for Merchants

MT Newswires Live
·
Sep 24

Musk Expands Business Empire Across the American Sun Belt with Massive Investments

Deep News
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24